Abstract:One of the main obstacles to the successful treatment of cancer is the phenomenon of drug resistance. A common strategy to overcome resistance is the use of combination therapies. However, the space of possibilities is huge and efficient search strategies are required. Machine Learning (ML) can be a useful tool for the discovery of novel, clinically relevant anti-cancer drug combinations. In particular, deep learning (DL) has become a popular choice for modeling drug combination effects. Here, we set out to examine the impact of different methodological choices on the performance of multimodal DL-based drug synergy prediction methods, including the use of different input data types, preprocessing steps and model architectures. Focusing on the NCI ALMANAC dataset, we found that feature selection based on prior biological knowledge has a positive impact—limiting gene expression data to cancer or drug response-specific genes improved performance. Drug features appeared to be more predictive of drug response, with a 41% increase in coefficient of determination (R 2 ) and 26% increase in Spearman correlation relative to a baseline model that used only cell line and drug identifiers. Molecular fingerprint-based drug representations performed slightly better than learned representations—ECFP4 fingerprints increased R 2 by 5.3% and Spearman correlation by 2.8% w.r.t the best learned representations. In general, fully connected feature-encoding subnetworks outperformed other architectures. DL outperformed other ML methods by more than 35% (R 2 ) and 14% (Spearman). Additionally, an ensemble combining the top DL and ML models improved performance by about 6.5% (R 2 ) and 4% (Spearman). Using a state-of-the-art interpretability method, we showed that DL models can learn to associate drug and cell line features with drug response in a biologically meaningful way. The strategies explored in this study will help to improve the development of computational methods for the rational design of effective drug combinations for cancer therapy. Cancer therapies often fail because tumor cells become resistant to treatment. One way to overcome resistance is by treating patients with a combination of two or more drugs. Some combinations may be more effective than when considering individual drug effects, a phenomenon called drug synergy. Computational drug synergy prediction methods can help to identify new, clinically relevant drug combinations. In this study, we developed several deep learning models for drug synergy prediction. We examined the effect of using different types of deep learning architectures, and different ways of representing drugs and cancer cell lines. We explored the use of biological prior knowledge to select relevant cell line features, and also tested data-driven feature reduction methods. We tested both precomputed drug features and deep learning methods that can directly learn features from raw representations of molecules. We also evaluated whether including genomic features, in addition to gene expression data, improves the predictive performance of the models. Through these experiments, we were able to identify strategies that will help guide the development of new deep learning models for drug synergy prediction in the future.

Optimizing drug synergy prediction through categorical embeddings in Deep Neural Networks

A systematic evaluation of deep learning methods for the prediction of drug synergy in cancer

A Deep Neural Network for Predicting Synergistic Drug Combinations on Cancer

DeepSynergy: predicting anti-cancer drug synergy with Deep Learning

HetBiSyn: Predicting Anticancer Synergistic Drug Combinations Featuring Bi-perspective Drug Embedding with Heterogeneous Data.

Synergistic Drug Combination Prediction by Integrating Multi-omics Data in Deep Learning Models

Deep graph embedding for prioritizing synergistic anticancer drug combinations

Deep learning-based multi-drug synergy prediction model for individually tailored anti-cancer therapies

CCSynergy: an integrative deep-learning framework enabling context-aware prediction of anti-cancer drug synergy

Predicting Combinative Drug Pairs Via Multiple Classifier System with Positive Samples Only

Optimal fusion of genotype and drug embeddings in predicting cancer drug response

Deep learning for predicting synergistic drug combinations: State‐of‐the‐arts and future directions

Anti-cancer Drug Synergy Prediction in Understudied Tissues using Transfer Learning

Harnessing machine learning to find synergistic combinations for FDA-approved cancer drugs

DSA-DeepFM: A Dual-Stage Attention-Enhanced DeepFM Model for Predicting Anticancer Synergistic Drug Combinations

How to Predict Effective Drug Combinations - Moving beyond Synergy Scores

Drug Synergistic Combinations Predictions via Large-Scale Pre-Training and Graph Structure Learning

Unlocking the therapeutic potential of drug combinations through synergy prediction using graph transformer networks

Prediction of Cancer Drug Combinations Based on Multidrug Learning and Cancer Expression Information Injection

MMSyn: A New Multimodal Deep Learning Framework for Enhanced Prediction of Synergistic Drug Combinations

GraphSynergy: a network-inspired deep learning model for anticancer drug combination prediction